Skip to content
Menu
The Ivermectin Journal
  • About
  • Contact
The Ivermectin Journal
October 18, 2021

Why Hype Merck’s Coronavirus Drug, But Dismiss Ivermectin?

By Pierre Kory – Pierre Kory, MD is president and chief medical officer of the Front-Line COVID-19 Critical Care Alliance.

“Merck claims that molnupiravir is highly effective against COVID, reducing hospitalizations by 50 percent. But this unpublished data hasn’t been peer-reviewed yet. Compare that to ivermectin.Numerous studies have shown it can reduce COVID hospitalization and death rates. Health ministries outside the U.S. report up to 76% reduction in hospitalization and 88% reduction in deaths when ivermectin is deployed in early “test and treat” programs. Government officials in Uttar Pradesh, India’s most populous state, credit a program centered around the widespread use of ivermectin with the near total eradication of the disease.

This is a better track record of efficacy than Merck has even claimed—let alone proven—for its new drug.”

https://www.realclearmarkets.com/articles/2021/10/15/why_does_the_fda_hype_mercks_covid_drug_but_dismiss_ivermectin_799071.html

Subscribe to be notified of new posts!

Loading

Recent Posts

  • Doctors Sue FDA, Allege Crusade Against Ivermectin ‘Unlawfully Interfered’ With Their Ability to Treat Patients June 8, 2022
  • New Hampshire House Approves Legislation To Allow The Use of Ivermectin March 22, 2022
  • Ivermectin Beats Out 9 Other Meds for Treating Omicron, Study Confirms February 17, 2022
  • Critical Thinker? Watch Sen. Ron Johnson’s “COVID-19: A Second Opinion” Video! February 4, 2022
  • Omicron FLCCC Protocol Update January 25, 2022
  • NEW Treatment Protocol: I-RECOVER Management Protocol for Long Haul COVID-19 January 25, 2022
  • Large Brazilian, peer-reviewed research study proves Ivermectin works January 24, 2022
  • Check out the FLCCC’s Healthy Holiday Gift Guide December 17, 2021
©2023 The Ivermectin Journal | Powered by WordPress and Superb Themes!